Landmark Study Finds Popular Surgery Provides No Relief For Osteoarthritis Of The Knee A landmark study conducted in London, Canada at The University of Western Ontario and Lawson
Health Research Institute shows that a routinely practiced knee surgery is ineffective at reducing joint pain or improving joint function for sufferers of osteoarthritis. The study appears in the New England Journal of
Medicine.
Source: www.medicalnewstoday.comHayborough Pharmacist Awarded For Excellence (SA), Australia Justin Turner, of Hayborough Pharmacy, was named as South Australian Pharmacist of the Year at the Pharmaceutical Society of Australia (SA Branch) awards night on September 8. The award was presented for Justin's "outstanding commitment to professional pharmacy services". In presenting the award, PSA (SA Branch) President Grant Kardachi commended Justin's achievements and commitment to delivering a range of professional pharmacy services.
Source: www.medicalnewstoday.comRetail Medical Clinics Attract Patients Who Do Not Have Regular Health Care Providers Retail medical clinics located in pharmacies and other stores typically attract insured and uninsured patients who are seeking help for a small group of easy-to-treat illnesses or preventive care and do not otherwise have a regular
health care provider, according to a new RAND Corporation study. "These clinics appear to attract patients who are not routine users of the current
health care system," said lead author Dr.
Source: www.medicalnewstoday.comJazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial Of Sodium Oxybate To Treat Fibromyalgia Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that the final patient has completed participation in the first Phase III pivotal clinical trial of JZP-6 (sodium oxybate) for the treatment of fibromyalgia. The JZP-6 Phase III clinical trial program includes two randomized, double blind, placebo-controlled studies. The first study enrolled 550 fibromyalgia patients at 65 centers in the U.S. The second Phase III study is enrolling patients at sites in the U.S.
Source: www.medicalnewstoday.comCerimon Pharmaceuticals Announces Positive Results From A Phase II Clinical Study Of Its Diclofenac Sodium Patch For Acute Pain Cerimon Pharmaceuticals, Inc., announced positive results from a Phase II clinical study of its once-daily, topical 15 mg (1%) diclofenac sodium patch. The multi-center SUPPORT (Stop Underlying Pain with a diclofenac Patch and Obtain Relief Topically) study evaluated the safety and efficacy of the Company's patch in 170 subjects with pain due to acute, mild-to-moderate ankle sprains.
Source: www.medicalnewstoday.comSpinal Restoration Completes Patient Enrollment In Its Study Of The Biostat Disc Augmentation System For The Treatment Of Discogenic Low Back Pain Spinal Restoration, Inc. announced it has completed enrollment in the Investigational Device Exemption (IDE) pilot study of the Biostat® Disc Augmentation System. Six month clinical results from this three site, 15 patient study are expected to be available in early 2009. The goal of the study is to examine the safety and efficacy of the Biostat Disc Augmentation System in the treatment of chronic discogenic low back pain resulting from Internal Disc Disruptions (IDD).
Source: www.medicalnewstoday.comSchering Plough Announces European Launch Of BRIDION(R) (Sugammadex) Schering-Plough Corporation (NYSE: SGP) announced that the European launch of BRIDION(R) (sugammadex) injection has begun with its introduction this week in Sweden, and that the product is expected to be available soon in the United Kingdom and Germany, with several other European markets to follow by the end of the year and in early 2009.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
